Announcements
- LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results
- LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference
- LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results
- LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)
- LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®
- Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
- LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
- LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
- LAVA Therapeutics to Participate in the H.C. Wainwright Immune Cell Engager Virtual Conference
More ▼
Key statistics
As of last trade LAVA Therapeutics NV (4PKB:BER) traded at 2.52, -32.62% below its 52-week high of 3.74, set on Mar 27, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.50 |
---|---|
High | 2.52 |
Low | 2.50 |
Bid | 2.38 |
Offer | 2.52 |
Previous close | 2.52 |
Average volume | 266.89 |
---|---|
Shares outstanding | 26.29m |
Free float | 18.74m |
P/E (TTM) | -- |
Market cap | 71.51m USD |
EPS (TTM) | -1.07 USD |
Data delayed at least 15 minutes, as of May 23 2024 14:36 BST.
More ▼